Case Study
Symeres: Advancing sustainable drug discovery and development
Headquartered in Europe, Symeres is a leading Contract Research Organization (CRO) specializing in integrated drug discovery and development services. With over 600 scientists and state-of-the-art facilities, the company provides end-to-end solutions from hit finding to clinical drug substance API manufacturing.
”Sustainability in pharmaceutical R&D is a strategic priority that enhances efficiency, compliance, and long-term resilience. At Symeres, we integrate sustainable practices into drug discovery and development to optimize resource use, improve process efficiency, and meet industry standards. This approach strengthens our operations and delivers value to our partners,
Jorg BenningshofHead of Scientific Operations at Symeres
patients, and stakeholders while aligning with evolving regulatory expectations.
Symeres ESG Pillars
Environment
- Carbon footprint
- Minimizing waste
- Efficient use of water and resources
Social
- Health and safety
- Employee well-being
- Contributing to local communities
Governance
- Transparency
- Risk management
- Ethical business practices
Aligned with:
Sustainability at Symeres:
A strategic approach
Symeres integrates sustainability across six key pillars:
-
Innovation and sustainable chemistry:
Leveraging green chemistry principles to reduce waste, improve process efficiency, and develop more sustainable synthesis routes. -
Energy efficiency and resource optimization:
Implementing strategies to lower energy consumption across research and production facilities. -
Responsible supply chain:
Collaborating with suppliers to ensure ethical sourcing of materials and promote responsible procurement.
-
Workforce well-being and inclusion:
Investing in a diverse and inclusive workplace, promoting employee safety, mental well-being, and continuous learning. -
Ethical business practices:
Maintaining strict regulatory compliance, integrity, and corporate responsibility throughout all operations. -
Community and scientific engagement:
Supporting educational initiatives, partnering with biotech innovators, and driving forward sustainable pharmaceutical development.
Sustainable impact in action
Dedicated ESG Task Force monitoring sustainability progress
